NEW YORK (GenomeWeb News) – Agilent Technologies said after the close of the market on Thursday that revenues for its fiscal fourth quarter were down 3 percent year over year, but the company still beat the average analyst estimate on the top and bottom lines.

For the three months ended Oc. 31, Agilent's total revenues dipped to $1.72 billion, compared to $1.77 billion a year ago, edging out the consensus Wall Street estimate of $1.71 billion.

The company had $1.83 billion in orders, up almost 5 percent from $1.75 billion a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.